Does pasireotide directly modulate skeletal muscle metabolism? - Wikidata - awgldk - TriplyDB

Does pasireotide directly modulate skeletal muscle metabolism?

Does pasireotide directly modulate skeletal muscle metabolism?

http://www.wikidata.org/entity/Q48307756

about

Neurodevelopmental Disorders and Environmental Toxicants: Epigenetics as an Underlying Mechanism

P2860

Q33711574-B6791BBA-C9FF-4A4C-810E-53A17F4D06E6

P2860

Does pasireotide directly modulate skeletal muscle metabolism?

http://www.wikidata.org/entity/Q48307756

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Does pasireotide directly modulate skeletal muscle metabolism?

@en

Does pasireotide directly modulate skeletal muscle metabolism?

@nl

type

label

Does pasireotide directly modulate skeletal muscle metabolism?

@en

Does pasireotide directly modulate skeletal muscle metabolism?

@nl

prefLabel

Does pasireotide directly modulate skeletal muscle metabolism?

@en

Does pasireotide directly modulate skeletal muscle metabolism?

@nl

P1433

Q48307756-4CBBCD7A-4CD1-47C6-9C9C-2A7FB33D9A2F

P1476

Q48307756-E70DEA36-8CBD-4BE2-9599-1E486308B23E

P2093

Q48307756-5FAE6052-BD72-4E92-8F9A-93AFF01CFAA1

P2860

Q48307756-18591B5C-DAE0-4868-96AB-202EA0BB61CE

Q48307756-3F3FA490-51C1-498C-9092-E6C214096736

Q48307756-417A0A9C-A801-4817-9449-DB49A807F963

Q48307756-6623AB30-6C0D-4BFE-93F4-ED7479532A79

Q48307756-7DBA1409-ED09-4CD4-BDE7-F5D4ABEBD753

Q48307756-800EB127-0129-42B6-A3C0-18069B9815C3

Q48307756-8EC638D2-1E58-4C1A-9CFB-0E2901C5CDD9

Q48307756-AFB5BC37-576D-46E3-B51E-9479B41C932D

Q48307756-DEA6C36D-BBCE-4F24-ADF9-C2F2DB94796D

P2888

Q48307756-3688625B-CE00-49D7-8F1F-F60708D36EE8

P304

Q48307756-04CDE1F7-43E9-4642-B8D3-3479CDB220D7

P31

Q48307756-179C3F02-78CD-4F58-9D8B-7EC91FA26616

Q48307756-454f0898-af37-4cb3-abcc-47145f24a3a6

P356

Q48307756-2CFF7D76-5FA3-44D2-B9FB-9B356455B5BB

P433

Q48307756-7C124E8E-DE64-4578-ADDD-47C8D1744823

P478

Q48307756-C08530D9-5F1E-42D0-9842-D65140B71799

P50

Q48307756-47FC733E-AEB7-4C1F-9604-118774140BA2

Q48307756-BBC1276A-19B9-44C4-ACF1-C0C529001259

P577

Q48307756-4EE39631-E589-410E-902E-2695DE0BBF3F

P698

Q48307756-96F59952-A97F-41A6-8BAD-FA0B10744855

P356

S12020-017-1291-8

P1433

P1476

Does pasireotide directly modulate skeletal muscle metabolism?

@en

P2093

Tullio Florio

http://www.w3.org/2001/XMLSchema#string

P2860

The Treatment of Cushing's Disease.

Agonist-biased signaling at the sst2A receptor: the multi-somatostatin analogs KE108 and SOM230 activate and antagonize distinct signaling pathways.

Anti-metastatic potential of somatostatin analog SOM230: Indirect pharmacological targeting of pancreatic cancer-associated fibroblasts.

Somatostatin receptors: from signaling to clinical practice.

Metabolic comorbidities in Cushing's syndrome.

SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile.

Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro.

Effects of pasireotide (SOM230) on protein turnover and p70S6 kinase-S6 ribosomal protein signaling pathway in rat skeletal muscle cells.

Pasireotide, an IGF-I action inhibitor, prevents growth hormone and estradiol-induced mammary hyperplasia.

P2888

s12020-017-1291-8

P304

6-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12020-017-1291-8

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

57

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-04-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28386722

http://www.w3.org/2001/XMLSchema#string